DX
Disease Modifying Therapy
Thursday, May 25, 2017: 6:15 PM-8:15 PM
B2 (New Orleans Convention Center)
Number Needed to Treat Analyses Comparing Outcomes in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Alemtuzumab or Ocrelizumab
Aaron Boster, MD, OhioHealth Neurological Physicians;
Raed Alroughani, MD, Amiri Hospital;
Regina Berkovich, MD, PhD, University of Southern California, Keck School of Medicine;
Giancarlo Comi, MD, University Vita-Salute San Raffaele;
Guillermo Izquierdo, MD, Virgen Macarena University Hospital;
Daniel Kantor, MD, Kantor Neurology;
Christopher LaGanke, MD, North Central Neurology Associates;
Richard AL Macdonell, MD, FRACP, Brain Research Institute, Florey Institute of Neuroscience and Mental Health;
Thibault Moreau, MD, University of Burgundy;
Basil Sharrack, MD, PhD, Sheffield Teaching Hospitals NHS Foundation Trust;
Heinz Wiendl, MD, University of Munster;
Bart Van Wijmeersch, MD, PhD, Rehabilitation & MS-Centre Overpelt, BIOMED, Hasselt University;
David H Margolin, MD, PhD, Sanofi Genzyme;
Karthinathan Thangavelu, PhD, Sanofi Genzyme;
Maria Melanson, MD, PhD, Sanofi Genzyme;
Mark S Freedman, MD, 1University of Ottawa, Ottawa Hospital Research Institute
The Effect of Ocrelizumab on Cognitive Functioning in Relapsing Multiple Sclerosis: Analysis of the Phase III IFN Beta-1a-Controlled OPERA Studies
Aaron E Miller, MD, Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai;
Jerome de Seze, MD PhD, University Hospital of Strasbourg;
Stephen L Hauser, MD, University of California, San Francisco;
Ludwig Kappos, MD, University Hospital Basel, University of Basel;
Jerry S Wolinsky, MD, McGovern Medical School, UTHealth;
Jian Han, PhD, Genentech Inc.;
Laura Julian, PhD, Genentech, Inc.;
Julie Napieralski, PhD, F. Hoffmann-La Roche Ltd;
Fred Lublin, MD, Icahn School of Medicine at Mount Sinai;
Aaron E Miller, MD, Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai
Disease-Modifying Drug Treatment before, during, and after Pregnancy in Women with Multiple Sclerosis and a Live Birth
Maria K Houtchens, MD, Brigham and Women's Hospital;
Natalie C Edwards, MSc, Health Services Consulting Corporation;
Amy L Phillips, PharmD, EMD Serono, Inc.;
Mary Lee, NA, Caudex;
Michele Springer, BA, Caudex
Time to Initiation of Disease-Modifying Drugs after a Live Birth in Women with Multiple Sclerosis
Maria K Houtchens, MD, Brigham and Women's Hospital;
Natalie C Edwards, MSc, Health Services Consulting Corporation;
Amy L Phillips, PharmD, EMD Serono, Inc.;
Mary Lee, NA, Caudex;
Michele Springer, BA, Caudex
Monofocal Posterior Fossa Natalizumab-Associated PML-IRIS
Ana Cristina Wing Marques dos Santos, Fellow, University of Western Ontario;
Marcelo Kremenchutzky, Director of London MS Clinics, University of Western Ontario;
Ana Cristina Wing Marques dos Santos, Fellow, University of Western Ontario
Post Hoc Analyses of PRISMS Study: Clinical Efficacy of Interferon beta-1a Subcutaneously Three Times Weekly According to Baseline Radiological Activity
Anthony T Reder, MD, University of Chicago;
Gary Cutter, PhD, University of Alabama at Birmingham;
Kathleen Hawker, MD, EMD Serono, Inc.;
Julie Aldridge, MS, EMD Serono, Inc.;
Flavia Nelson, MD, University of Texas - McGovern Medical School;
Mary Lee, NA, Caudex;
Michele Springer, BA, Caudex
Durable Efficacy of Alemtuzumab on MRI Disease Activity over 6 Years in Treatment-Naive RRMS Patients with Highly Active Disease: Care-MS I Extension
Anthony Traboulsee, MD, University of British Columbia;
Michael Barnett, PhD, MD, University of Sydney;
Regina Berkovich, MD, PhD, University of Southern California, Keck School of Medicine;
Aaron Boster, MD, OhioHealth Neurological Physicians;
Giancarlo Comi, MD, University Vita-Salute San Raffaele;
Christopher Laganke, MD, North Central Neurology Associates;
Daniel Pelletier, MD, Keck School of Medicine of University of Southern California;
Alex Rovira, MD, Vall d'Hebron University Hospital;
Sven Schippling, MD, Neuroimmunology and Multiple Sclerosis Research, University Hospital Zurich and University of Zurich;
Barry A Singer, MD, MS Center for Innovations in Care, Missouri Baptist Medical Center;
David H Margolin, MD, PhD, Sanofi Genzyme;
Sourav Santra, PhD, Cytel;
Douglas L Arnold, MD, Montreal Neurological Institute, McGill University;
on behalf of the CARE-MS I and CAMMS03409 Investigators, n/a, n/a
Persistence and Adherence to Fingolimod or Brace Therapy Among Medicaid Patients with Multiple Sclerosis in Missouri
Ashok Vegesna, PharmD, Novartis Pharmaceuticals Corporation;
Huanxue Zhou, MS, KMK Consulting, Inc.;
John J Ko, Pharm.D., MS, Novartis Pharmaceuticals Corporation;
Dendy Macaulay, PhD, Analysis Group, Inc.;
Jenny Zhou, PhD, Analysis Group, Inc.;
Luke Schmerold, BS, Analysis Group, Inc.;
Cassie Tang, MS, Analysis Group, Inc.;
James Signorovitch, PhD, Analysis Group, Inc.;
Ashok Vegesna, PharmD, Novartis Pharmaceuticals Corporation
Treatment Satisfaction with Daclizumab in the Extend Study
Bhupendra Khatri, MD, Wheaton Franciscan Health Care St. Francis Hospital;
Stanley Cohan, MD, PhD, Providence Multiple Sclerosis Center;
Sibyl Wray, MD, Hope Neurology MS Center;
Xiaolan Ye, PhD, AbbVie;
Oksana Mokliatchouk, PhD, Biogen;
Sami Fam, PhD, Biogen;
Craig Wakeford, MA, Biogen;
Bhupendra Khatri, MD, Wheaton Franciscan Health Care St. Francis Hospital
Evaluation of Efficacy and Tolerability of Sc IFN Beta 1-a Given Three Times per Week in an Older Multiple Sclerosis Population
Bianca Weinstock-Guttman, MD, University at Buffalo;
Caila B Vaughn, PhD, MPH, University at Buffalo;
Katelyn S. Kavak, MS, Jacobs MS Center for Treatment and Research;
Barbara E. Teter, PhD, MPH, New York State Multiple Sclerosis Consortium;
S. Ahmed Sanai, MD, University at Buffalo;
Andrew Goodman, MD, New York State Multiple Sclerosis Consortium;
Patricia K Coyle, MD, New York State Multiple Sclerosis Consortium;
Lauren Krupp, MD, Pediatric MS Center, NYU Langone Medical Center;
Malcolm Gottesman, MD, NYU Winthrop Hospital;
Keith R Edwards, MD, New York State Multiple Sclerosis Consortium;
Caila B Vaughn, PhD, MPH, University at Buffalo
Effect of Phenylephrine on Injection Site Reactions in Multiple Sclerosis Patients Treated with Plegridy (peginterferon beta-1a)
Lisa Laing, BSN, RN, MSCN, NYU Langone Medical Center;
Shannon Haas, MS, NYU School of Medicine;
Maayan Elyashiv, BS, NYU School of Medicine;
Carrie L Sammarco, DNP, FNP-C, MSCN, NYU Langone Medical Center;
Cara Desanctis, BSN, RN, MSCN, NYU Langone Medical Center;
Shannon Haas, MS, NYU School of Medicine
Rapid Elimination Procedure of Teriflunomide with Colestipol Hydrochloride (TERCOL)
Crystal Dixon, MD, University of South Florida;
Angela Aungst, MPH, University of South Florida;
Yasir Durrani, MBBS, University of South Florida;
Lise Casady, ARNP, University of South Florida;
Derrick Robertson, MD, University of South Florida;
Crystal Dixon, MD, University of South Florida;
Derrick Robertson, MD, University of South Florida
Characteristics of Treatment-Naive Patients Initiating Subcutaneous Peginterferon Beta-1a Vs. Subcutaneous Interferon Beta-1a in the United States
Daniel Jones, PhD, Biogen;
Mehul Jhaveri, PharmD, MPH, Biogen;
Ning Wu, PhD, Biogen;
Kun Yang, PharmD, Biogen;
Crystal Watson, MS, Biogen;
Daniel Jones, PhD, Biogen
Lemtrada® (Alemtuzumab) Pregnancy Exposure Registry: Study Design and Enrollment for Pregnant Women with Multiple Sclerosis Exposed to Alemtuzumab
David Rog, MD, MRCP, Salford Royal NHS Foundation Trust;
Nicola Seferta, N/A, Salford Royal NHS Foundation Trust;
Tatiana Mihalova, MRCP, Salford Royal NHS Foundation Trust;
Miqun Robinson, MD, PhD, Sanofi Genzyme;
Susan Colilla, PhD, MPH, Sanofi Genzyme;
Yang Zhao, PhD, Sanofi Genzyme;
Tanya Z Fischer, MD, PhD, Sanofi Genzyme;
David H Margolin, MD, PhD, Sanofi Genzyme
The Association Between Confirmed Disability Progression and Patient-Reported Fatigue in Patients with PPMS in the ORATORIO Study
Deborah M Miller, PhD, LISW, Cleveland Clinic;
Stephen L Hauser, MD, University of California, San Francisco;
Ludwig Kappos, MD, University Hospital Basel, University of Basel;
Fred Lublin, MD, Icahn School of Medicine at Mount Sinai;
Xavier Montalban, MD, PhD, Vall d'Hebron University Hospital;
Fiona Mc Dougall, PhD, ClinPsyD, Roche Products Limited;
Gurpreet Deol-Bhullar, BSc, OT, F. Hoffmann-La Roche Ltd;
Jian Han, PhD, Genentech Inc.;
Laura Julian, PhD, Genentech, Inc.;
Bruno Musch, MD, PhD, Genentech Inc.;
Jerry S Wolinsky, MD, McGovern Medical School, UTHealth;
Deborah M MIller, PhD, LISW, Cleveland Clinic
Comparison of Blood Lymphocyte Counts and Reported Rates of Infection in Patients Treated with Fingolimod and iDMTs in PREFERMS
Edward J Fox, MD, Central Texas Neurology Consultants;
Florian P Thomas, MD, PhD, MA, Hackensack University Medical Center;
Mark Cascione, MD, Tampa Neurology Associates;
Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation;
Lesley Schofield, PhD, Novartis Pharmaceuticals Corporation;
Fernanda Boulos, MD, Novartis Pharmaceuticals Corporation;
Nadia Tenenbaum, MD, Novartis Pharmaceuticals Corporation
Safety Monitoring for Disease Modifying Therapies in Multiple Sclerosis: Patient and Provider Adherence
Felecia Hart, PharmD, MSCS, University of Colorado;
Jacquelyn Bainbridge, PharmD, FCCP, MSCS, University of Colorado;
Augusto A Miravalle, M.D., University of Colorado;
Felecia Hart, PharmD, MSCS, University of Colorado
Comparison of Treatment Retention and Satisfaction with Fingolimod, Interferons and Glatiramer Acetate in PREFERMS
Florian P Thomas, MD, PhD, MA, Hackensack University Medical Center;
Douglas L Arnold, MD, NeuroRx Research;
Mark Cascione, MD, Tampa Neurology Associates;
Edward J Fox, MD, Central Texas Neurology Consultants;
Maria C Vieria, MD, Novartis Pharmaceuticals Corporation;
John J Ko, Pharm.D., MS, Novartis Pharmaceuticals Corporation;
Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation;
Lesley Schofield, PhD, Novartis Pharmaceuticals Corporation;
Fernanda Boulos, MD, Novartis Pharmaceuticals Corporation;
Nadia Tenenbaum, MD, Novartis Pharmaceuticals Corporation;
Bruce AC Cree, MD, PhD, University of California
Subgroup and Sensitivity Analyses of Treatment Retention in Patients Participating in the PREFERMS Study
Florian P Thomas, MD, PhD, MA, Hackensack University Medical Center;
Bruce AC Cree, MD, PhD, University of California;
Heidi Crayton, MD, MS Center of Greater Washington;
Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation;
Lesley Schofield, PhD, Novartis Pharmaceuticals Corporation;
Fernanda Boulos, MD, Novartis Pharmaceuticals Corporation;
Nadia Tenenbaum, MD, Novartis Pharmaceuticals Corporation
Durable Efficacy of Cladribine Tablets in Patients with Multiple Sclerosis: Analysis of Relapse Rates and Relapse-Free Patients in the CLARITY and CLARITY Extension Studies
Gavin Giovannoni, MD, Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry;
Giancarlo Comi, MD, University Vita-Salute San Raffaele;
Stuart Cook, MD, Rutgers, The State University of New Jersey;
Peter Rieckmann, MD, Akademisches Krankenhaus Sozialstiftung Bamberg;
Kottil Rammohan, MD, Ohio State University Hospital;
Per Soelberg-Sorensen, MD, Copenhagen University Hospital;
Patrick Vermersch, MD, University of Lille;
Christine Hicking, MS, Merck KGaA;
Abidemi Adeniji, PhD, EMD Serono, Inc.;
Fernando Dangond, MD, EMD Serono, Inc.;
Mary Lee, NA, Caudex;
Michele Springer, BA, Caudex
Benefits of Cladribine Tablets on No Evidence of Disease Activity (NEDA) Status in Patients with Multiple Sclerosis: Analysis of Pooled Data from CLARITY and ONWARD
Gavin Giovannoni, MD, Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry;
Xavier Montalban, MD, Hospital Universitari Vall d'Hebron;
Christine Hicking, MS, Merck KGaA;
Fernando Dangond, MD, EMD Serono, Inc.;
Mary Lee, NA, Caudex;
Michele Springer, BA, Caudex
Benefits of Cladribine Tablets on Magnetic Resonance Imaging (MRI) Outcomes in Patients with Multiple Sclerosis: Analysis of Pooled Data from the CLARITY and ONWARD Studies
Gavin Giovannoni, MD, Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry;
Giancarlo Comi, MD, University Vita-Salute San Raffaele;
Xavier Montalban, MD, Hospital Universitari Vall d'Hebron;
Christine Hicking, MS, Merck KGaA;
Fernando Dangond, MD, EMD Serono, Inc.;
Mary Lee, NA, Caudex;
Michele Springer, BA, Caudex
Benefits of Cladribine Tablets on Relapse Rates and Disability Progression in Patients with Multiple Sclerosis: Analysis of Pooled Data from the CLARITY and ONWARD Studies
Gavin Giovannoni, MD, Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry;
Xavier Montalban, MD, Hospital Universitari Vall d'Hebron;
Christine Hicking, MS, Merck KGaA;
Fernando Dangond, MD, EMD Serono, Inc.;
Mary Lee, NA, Caudex;
Michele Springer, BA, Caudex
Cladribine Tablets in the ORACLE-MS Study Open-Label Maintenance Period: Analysis of Efficacy in Patients After Conversion to Clinically Definite Multiple Sclerosis (CDMS)
Giancarlo Comi, MD, University Vita-Salute San Raffaele;
Thomas Leist, MD, Thomas Jefferson University;
Mark S Freedman, MD, University of Ottawa and the Ottawa Hospital Research Institute;
Bruce AC Cree, MD, PhD, University of California;
Patricia K Coyle, MD, Stony Brook University;
Hans-Peter Hartung, MD, Heinrich-Heine University;
Patrick Vermersch, MD, University of Lille;
Doris Damian, PhD, EMD Serono, Inc.;
Fernando Dangond, MD, EMD Serono, Inc.;
Mary Lee, NA, Caudex;
Michele Springer, BA, Caudex
Treatment with Alemtuzumab in Relapsing Remitting Multiple Sclerosis Patients: The British Columbia Experience
Heather Yong, Undergraduate Student, University of British Columbia;
Philippe Beauchemin, MD, UBC MS Clinic;
Robert Carruthers, MD, University of British Columbia;
Krista Barclay, RN, University of British Columbia;
Virginia Devonshire, MD, University of British Columbia;
Ana-Luiza Sayao, MD, University of British Columbia;
Anthony Traboulsee, MD, University of British Columbia;
Heather Yong, Undergraduate Student, University of British Columbia
Neurocognitive Function over 24 Months in Patients with RRMS Initiating Alemtuzumab in Routine Clinical Practice: LEM-COG Study Design
Jeffrey Wilken, PhD, Washington Neuropsychology Research Group;
Timothy Fratto, PhD, Washington Neuropsychology Research Group;
Robert L Kane, PhD, ABPP-CN, University of Maryland School of Medicine;
Shannon Kolind, PhD, University of British Columbia;
Akanksha Mittal, PhD, Sanofi Genzyme;
Alan K Jacobs, MD, Sanofi Genzyme;
Anthony Traboulsee, MD, University of British Columbia
Long-Term Outcomes for Subgroup of Patients with a Primary Presentation of Optic Neuritis in the TOPIC Extension Study
Jiwon Oh, MD, St. Michael's Hospital, University of Toronto;
Ludwig Kappos, MD, University Hospital Basel, University of Basel;
Giancarlo Comi, MD, University Vita-Salute San Raffaele;
Mark S Freedman, MD, University of Ottawa and the Ottawa Hospital Research Institute;
Jerome de Seze, MD PhD, University Hospital of Strasbourg;
Jerry S Wolinsky, MD, University of Texas Health Science Center at Houston;
Philippe Truffinet, MD, Sanofi;
Myriam Benamor, MD, Sanofi;
Karthinathan Thangavelu, PhD, Sanofi Genzyme;
Aaron E Miller, MD, Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai;
Heather St Michael, BSc, Fishawack
Monthly 3T MRI in MS Patients Switched from Natalizumab to Teriflunomide in a Controlled, Prospective Study
Keith R Edwards, MD, MS Center of Northeastern New York;
Stanley Cohan, MD, PhD, Providence Multiple Sclerosis Center;
Lore Garten, MD, Ph. D., MS Center of Northeastern New York;
James Thomas, M.D., Community Care Physicians, P.C.;
Kyle E Smoot, MD, Providence Multiple Sclerosis Center;
Kiren Kresa-Reahl, MD, Providence Multiple Sclerosis Center;
Judy O'Connor, BSW, CCRC, MS Center of Northeastern New York;
Tiffany Gervasi, Clinical Research Coordinator, Providence Multiple Sclerosis Center;
Chiayi Chen, Ph.D., Providence Multiple Sclerosis Center;
Jessica Siuta, BSMT, ASCP, Clinical Research Coordinator, MS Center of Northeastern New York;
Vineetha Kamath, BS, MS Center of Northeastern New York;
Vineetha Kamath, BS, MS Center of Northeastern New York
Association Between Fingolimod and HPV-Related Complications in Women with MS
Kendra L Yale, MMS, PA-C, MSCS, University of Colorado;
Kristin Stockman, MSN, ANP-BC, MSCS, University of Colorado;
Shannon Cornell, MSN, ANP-BC, MSCS, University of Colorado;
Kendra L Yale, MMS, PA-C, MSCS, University of Colorado
Rates of Comorbidities in Patients with and without Multiple Sclerosis: A US Retrospective Claims Database Analysis
Kiren Kresa-Reahl, MD, Providence MS Center;
Natalie C Edwards, MSc, Health Services Consulting Corporation;
Gary Schneider, ScD, Boston Health Economics, Inc.;
Kevin Stern, BS, Boston Health Economics, Inc.;
Amy L Phillips, PharmD, EMD Serono, Inc.;
Mary Lee, NA, Caudex;
Michele Springer, BA, Caudex
Microscopic Hematuria in Patients on Tecfidera
Kirstin Nygren, MSN, FNP-BC, MSCN, UCLA;
Barbara Giesser, MD, UCLA;
Kirstin Nygren, MSN, FNP-BC, MSCN, UCLA
Natalizumab in Anti-JCV Antibody Negative Patients with Early RRMS: Prespecified Analysis of Optical Coherence Tomography (OCT) and Visual Acuity Data
Laura J Balcer, MD, MSCE, New York University Langone Medical Center;
Steven Galetta, MD, New York University Langone Medical Center;
Jai Perumal, MD, Judith Jaffe Multiple Sclerosis Center;
Roumen Balabanov, MD, Rush University Multiple Sclerosis Center;
Robert J Fox, MD, Cleveland Clinic;
Qunming Dong, MD, Biogen;
Shavy Makh, MPhil, Biogen;
Christophe Hotermans, MD, Biogen;
John S Walsh, MD, Biogen;
Denise Campagnolo, MD, Formerly Biogen;
Lily Lee, MD, Biogen;
Christina Eavis, BS, Infusion, an Ashfield company, part of UDG Healthcare;
Lily Lee, MD, Biogen
Infusion-Related Reactions with Ocrelizumab: Pooled Analysis of the Open-Label Extension of the Phase III, Interferon Beta-1a-Controlled OPERA Studies
Lori Mayer, DNP, MSN, RN, Central Texas Neurology Consultants, Multiple Sclerosis Clinic of Central Texas;
Ludwig Kappos, MD, University Hospital Basel, University of Basel;
Michael K Racke, MD, Wexner Medical Center, Ohio State University;
Kottil Rammohan, MD, University of Miami;
Anthony Traboulsee, MD, University of British Columbia;
Jerry S Wolinsky, MD, McGovern Medical School, UTHealth;
Cathy Chognot, PhD, F. Hoffmann-La Roche Ltd;
Laura Julian, PhD, Genentech, Inc.;
Julie Napieralski, PhD, F. Hoffmann-La Roche Ltd;
Johan van Beek, PhD, F. Hoffmann-La Roche Ltd;
Hanzhe Zheng, PhD, Genentech, Inc.;
Stephen L Hauser, MD, University of California, San Francisco;
Lori Mayer, DNP, MSN, RN, Central Texas Neurology Consultants, Multiple Sclerosis Clinic of Central Texas
Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis
Ludwig Kappos, MD, PhD, University Hospital Basel, University of Basel;
Stephen L Hauser, MD, University of California, San Francisco;
Xavier Montalban, MD, PhD, Vall d’Hebron University Hospital;
Regine Buffels, MD, F. Hoffmann-La Roche Ltd;
Peter Chin, MD, Genentech Inc.;
Carrie Li, PhD, F. Hoffmann-La Roche Ltd;
Deborah Mortensen, BA, Genentech, Inc.;
Julie Napieralski, PhD, F. Hoffmann-La Roche Ltd;
Johan van Beek, PhD, F. Hoffmann-La Roche Ltd;
David Wormser, MSc, MPhil PhD, F. Hoffmann-La Roche Ltd;
Jerry S Wolinsky, MD, McGovern Medical School, UTHealth;
Ashley J Porter, PhD, Articulate Science
Characteristics of Patients Switching to Subcutaneous Peginterferon Beta-1a Vs. Subcutaneous Interferon Beta-1a in the United States
Mehul Jhaveri, PharmD, MPH, Biogen;
Ning Wu, PhD, Biogen;
Crystal Watson, MS, Biogen;
Kun Yang, PharmD, Biogen;
Daniel Jones, PhD, Biogen;
Mehul Jhaveri, PharmD, MPH, Biogen
Safety and Effectiveness of Delayed-Release Dimethyl Fumarate in a Canadian Cohort Enrolled in the ESTEEM Study
Konstantin Balashov, MD, Rutgers University;
Richard AL Macdonell, MD, Austin Health and Florey Institute of Neuroscience and Mental Health;
Kathryn Giles, MD, MSc, FRCPC, Cambridge Memorial Hospital;
Nicholas Everage, PhD, Biogen;
Claudia Prada, MD, PhD, Biogen;
Katherine Riester, MPH, Biogen;
Dane Cloutier, MSc, Biogen;
Mihaela Vlaicu, MD, Biogen;
Mihaela Vlaicu, MD, Biogen
Socio-Economic Disparity in Treatment and Healthcare Resource Use in Patients with Multiple Sclerosis Covered By Medicaid
Mitzi J Williams, MD, Multiple Sclerosis Center of Atlanta;
Lilyana Amezcua, MD, MS, University of Southern California;
Alexander Green, MD, MPH, Massachusetts General Hospital, Harvard Medical School;
Hollie Schmidt, MS, Accelerated Cure Project for MS;
Jia Zhou, MS, Biogen;
Qiang Hou, PhD, Biogen;
Jaanai Babb, PharmD, Biogen;
Jessica Royall, MBA, Biogen;
Terrie Livingston, PharmD, Biogen;
Terrie Livingston, PharmD, Biogen
Teriflunomide Real-World Outcomes from the US Cohort of the Phase 4 Teri-PRO Study
Patricia K Coyle, MD, Stony Brook University;
Bhupendra Khatri, MD, The Regional MS Center, Center for Neurological Disorders at Wheaton Franciscan Healthcare;
Keith R Edwards, MD, Multiple Sclerosis Center of Northeastern New York;
Steve Cavalier, MD, Sanofi Genzyme;
Pascal Rufi, MD, Sanofi Genzyme;
Karthinathan Thangavelu, PhD, Sanofi Genzyme;
Myriam Benamor, MD, Sanofi;
Ralf Gold, MD, St Josef Hospital, Ruhr University Bochum;
Heather St Michael, BSc, Fishawack
Using Acthar in Lemtrada Infusion Protocol
Patricia A Pagnotta, ARNP, MSN, MSCN, CCRN, Neurology Associates, PA;
Christopher LaGanke, MD, North Central Neurology Associates;
Constance B Easterling, RN, MSN, ANP, MSCN, Multiple Sclerosis Care Center of Neurological Services;
Patricia A Pagnotta, ARNP, MSN, MSCN, CCRN, Neurology Associates, PA
Perceptions Regarding the FDA Approval of MS Therapies
Paul Ford, Ph.D., Cleveland Clinic;
Stacey S Cofield, PhD, University of Alabama at Birmingham;
Tuula Tyry, PhD, Dignity Health, St. Joseph's Hospital and Medical Center;
Carol Cosenza, MSW, University of Massachusetts, Boston;
Amber Salter, PhD, Washington University in St. Louis;
Mary Beth Mercer, MPH, Cleveland Clinic;
Sneha Natarajan, PhD, Cleveland Clinic;
Lauren Cripps, MA, University of Massachusetts, Boston;
Gary Cutter, PhD, University of Alabama at Birmingham;
Robert J Fox, MD, Cleveland Clinic;
Stacey S Cofield, PhD, University of Alabama at Birmingham
Short- and Long-Term Predictors of Relapse or Disability Worsening in Patients with Multiple Sclerosis in the Phase 3 FREEDOMS and FREEDOMS II Studies
Aaron Boster, MD, OhioHealth Neurological Physicians;
Pavle Repovic, MD, PhD, Multiple Sclerosis Center, Swedish Neuroscience Institute;
Shannon Ritter, MS, Novartis Pharmaceuticals Corporation;
Davorka Tomic, PhD, Novartis Pharma AG;
Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation;
Daniela P Meier, MD, Novartis Pharma AG;
Fernanda Boulos, MD, Novartis Pharmaceuticals Corporation;
Frederik Barkhof, MD, PhD, VU University Medical Center;
Till Sprenger, MD, University Hospital Basel
Short- and Long-Term Predictors of Relapses or Disability Worsening in Patients with Multiple Sclerosis in the Phase 3 TRANSFORMS Study
Aaron Boster, MD, OhioHealth Neurological Physicians;
Pavle Repovic, MD, PhD, Multiple Sclerosis Center, Swedish Neuroscience Institute;
Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation;
Daniela P Meier, MD, Novartis Pharma AG;
Fernanda Boulos, MD, Novartis Pharmaceuticals Corporation;
Till Sprenger, MD, University Hospital Basel;
Frederik Barkhof, MD, PhD, VU University Medical Center
Improved Processing Speed on Fingolimod Therapy: Oral Symbol Digit Modalities Test Response in PREFERMS
Ralph H Benedict, PhD, University at Buffalo;
Douglas L Arnold, MD, NeuroRx Research;
Bruce AC Cree, MD, PhD, University of California;
Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation;
Lesley Schofield, PhD, Novartis Pharmaceuticals Corporation;
Fernanda Boulos, MD, Novartis Pharmaceuticals Corporation;
Nadia Tenenbaum, MD, Novartis Pharmaceuticals Corporation
Post Hoc Analysis of PRISMS Study: Efficacy of Interferon beta-1a Subcutaneously Three Times Weekly According to Baseline EDSS/Duration, EDSS, and MSSS Subgroups
Regina Berkovich, MD, University of Southern California;
Hao Zhang, PhD, EMD Serono, Inc.;
Julie Aldridge, MS, EMD Serono, Inc.;
Scott Baver, PhD, EMD Serono, Inc.;
Eric Williamson, MD, University of Pennsylvania Penn Neuroscience Center;
Mary Lee, NA, Caudex;
Michele Springer, BA, Caudex
Efficacy and Safety of Teriflunomide in Asian Patients with Relapsing Forms of MS: A Subgroup Analysis of the Phase 3 TOWER Study
Richard AL Macdonell, MD, Austin Health;
Mark S Freedman, MD, University of Ottawa and the Ottawa Hospital Research Institute;
Xianhao Xu, MD, Beijing Hospital;
Steve Vucic, MD, University of Sydney;
Philippe Truffinet, MD, Sanofi;
Myriam Benamor, MD, Sanofi;
Karthinathan Thangavelu, PhD, Sanofi Genzyme;
Aaron E Miller, MD, Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai;
Heather St Michael, BSc, Fishawack
EVOLVE-MS-2: Randomized, Double-blind Phase 3 Study of Gastrointestinal Tolerability for ALKS 8700 Versus Dimethyl Fumarate in Relapsing-Remitting Multiple Sclerosis
Robert T Naismith, MD, Washington University School of Medicine;
Richard A Leigh-Pemberton, MD, Alkermes, Inc.;
Amy E Claxton, PhD, Alkermes, Inc.;
Marjie L Hard, Ph.D., Alkermes, Inc.;
Yangchun Du, PhD, Alkermes, Inc.;
Lisa von Moltke, MD, Alkermes, Inc.;
Anthony J Lembo, MD, Beth Israel Deaconess Medical Center;
Jerry Wolinsky, MD, University of Texas Health Science Center at Houston;
Robert T Naismith, MD, Washington University School of Medicine
Effect of Teriflunomide on Cortical Atrophy in a Subgroup Analysis of Patients Presenting with Optic Neuritis in the Phase 3 TOPIC Study
Robert Zivadinov, MD, University at Buffalo;
Michael G Dwyer, PhD, University at Buffalo;
Ellen Carl, PhD, University at Buffalo;
Karthinathan Thangavelu, PhD, Sanofi Genzyme;
Steve Cavalier, MD, Sanofi Genzyme;
Niels Bergsland, PhD, University at Buffalo;
Heather St Michael, BSc, Fishawack
Effects of DMTs on Lymphocytes and Infections
Salvatore Q Napoli, MD, Neurology Center of New England P.C.;
Sarah B Cardoso, Research Coordinator, Neurology Center of New England P.C.;
Salvatore Q Napoli, MD, Neurology Center of New England P.C.;
Sarah B Cardoso, Research Coordinator, Neurology Center of New England P.C.
Fatal CNS Hemorrhage in a Patient with Relapsing-Remitting MS Who Received Alemtuzumab
Samuel F Hunter, MD, PhD, Advanced Neurosciences Institute;
David H Margolin, MD, PhD, Sanofi Genzyme;
Kastytis Sestakauskas, MD, Sanofi Research & Development;
James Thomas, MD, Sanofi Genzyme;
Claudio E Rodriguez, MD, Sanofi Genzyme;
Vladimir Evilevitch, MD, Sanofi Genzyme;
Alan K Jacobs, MD, Sanofi Genzyme
Real-World, Individualized, Comprehensive Patient Education and Support Procedures to Optimize Treatment Experience with Alemtuzumab
Santrina Fletcher, RN, MSN, CNP, Riverhills Neuroscience;
Rhonda Cortright, MSCS, Riverhills Neuroscience;
Mary Pat Bartoszek, CNP, MSCN, Sanofi Genzyme;
Colleen E Miller, DNS, Sanofi Genzyme
Interferon Associated Retinopathy in a Patient with Relapsing Remitting Multiple Sclerosis
Sara Razmjou, MD, M.Sc, Wayne State School of Medicine;
Maziar Eslami Farsani, MD, Wayne State School of Medicine;
Sheridan Reed, BS, Wayne State School of Medicine;
Samuel Lichtman-Mikol, BA, Wayne State School of Medicine;
Navid Seraji-Bozorgzad, MD, M.Sc, Wayne State School of Medicine;
Evanthia Bernitsas, MD, Wayne State University School of Medicine;
Sara Razmjou, MD, M.Sc, Wayne State School of Medicine;
Evanthia Bernitsas, MD, Wayne State University School of Medicine
Pregnancy Outcomes Following Ocrelizumab Treatment in Patients with Multiple Sclerosis and Other Autoimmune Diseases
Sibyl Wray, MD, Hope Neurology MS Center;
Silvia Bader-Weder, MD, F. Hoffmann-La Roche Ltd;
Regine Buffels, MD, F. Hoffmann-La Roche Ltd;
Donna Masterman, MD, MS, Genentech Inc.;
Julie Napieralski, PhD, F. Hoffmann-La Roche Ltd;
Stephen L Hauser, MD, University of California, San Francisco;
Inderjit Chhatwal, MSc, Articulate Science
Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: An Integrated Analysis of Infections in Association with Severe Lymphopenia
Stuart Cook, MD, Rutgers, The State University of New Jersey;
Thomas Leist, MD, Thomas Jefferson University;
Giancarlo Comi, MD, University Vita-Salute San Raffaele;
Xavier Montalban, MD, Hospital Universitari Vall d'Hebron;
Elke Sylvester, MD, Merck KGaA;
Christine Hicking, MS, Merck KGaA;
Fernando Dangond, MD, EMD Serono, Inc.;
Mary Lee, NA, Caudex;
Michele Springer, BA, Caudex
Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: An Integrated Analysis of Safety from the Multiple Sclerosis Clinical Development Program
Stuart Cook, MD, Rutgers, The State University of New Jersey;
Thomas Leist, MD, Thomas Jefferson University;
Giancarlo Comi, MD, University Vita-Salute San Raffaele;
Xavier Montalban, MD, Hospital Universitari Vall d'Hebron;
Elke Sylvester, MD, Merck KGaA;
Christine Hicking, MS, Merck KGaA;
Fernando Dangond, MD, EMD Serono, Inc.;
Mary Lee, NA, Caudex;
Michele Springer, BA, Caudex
Reduction of Lymphopenia by Cladribine Tablets Under Retreatment Guidelines: A Long-Term Follow-Up Analysis of Patients in the ORACLE-MS Study
Thomas Leist, MD, Thomas Jefferson University;
Giancarlo Comi, MD, University Vita-Salute San Raffaele;
Mark S Freedman, MD, University of Ottawa and the Ottawa Hospital Research Institute;
Bruce AC Cree, MD, PhD, University of California;
Patricia K Coyle, MD, Stony Brook University;
Hans-Peter Hartung, MD, Heinrich-Heine University;
Patrick Vermersch, MD, University of Lille;
Elke Sylvester, MD, Merck KGaA;
Doris Damian, PhD, EMD Serono, Inc.;
Fernando Dangond, MD, EMD Serono, Inc.;
Mary Lee, NA, Caudex;
Michele Springer, BA, Caudex
The Impact of Natalizumab on Health-Related Quality of Life in Patients with Secondary-Progressive Multiple Sclerosis
Mark S Freedman, MD, 1University of Ottawa, Ottawa Hospital Research Institute;
Douglas Jeffery, MD, PhD, Piedmont HealthCare;
Aaron E Miller, MD, Icahn School of Medicine at Mount Sinai;
Eva Havrdova, MD, PhD, First Faculty of Medicine and General University Hospital, Charles University in Prague;
Finn Sellebjerg, MD, PhD, DMSci, Danish Multiple Sclerosis Center, Ringshospitalet, University of Copenhagen;
Hans-Peter Hartung, MD, Heinrich-Heine University;
Ih Chang, PhD, Biogen;
Sarah Naoshy, MPH, Biogen;
Nolan Campbell, PhD, Biogen;
Christina Eavis, BS, Infusion, an Ashfield company, part of UDG Healthcare
